Photo: Joe Raedle / Getty Images
Although the use of the same vaccine will be prioritized, it will be possible to combine the brands when receiving the booster dose. Press reports anticipate that this could be the announcement of the Food and Drug Administration (FDA) midweek, and they do it by citing people with knowledge of the subject, who preferred to hide their identity.
The New York Times indicates that the government will not recommend one brand over another.
For its part, The Washington Post emphasizes that this announcement will come within the framework of another: the Booster Authorization for Moderna and Johnson & Johnson Vaccines.
It was in September when the agency authorized the use of a booster dose for those over 65 and people with high health risks, in the case of Pfizer.
Added to this is the regulator’s advisory panel, which also points to Johnson & Johnson and Moderna.
In August, the White House announced that it plans a widespread vaccine booster campaign, which is still pending clearance from both the FDA and the Centers for Disease Control and Prevention.
Among the 188 million Americans fully vaccinated, the vast majority received Pfizer or Moderna, while only about 15 million received that of Johnson & Johnson.
A study by an expert advisory committee for the FDA showed that those who received the latter saw their antibody levels increase 76 times in 15 days when receiving Pfizer or Moderna, versus a four-fold increase when receiving another dose of Johnson & Johnson.
This also interests you:
– It will be on November 8: the United States announces the date of the reopening of the border
– List of vaccines against covid-19 authorized to enter the United States
– Step by step to obtain your vaccination certificate in Mexico